Which pulmonary function tests best differentiate between COPD phenotypes?

Respiratory Care

Volumn 57, Issue 1, 2012, Pages 50-60

  Salzman, Steve H ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

COPD; Mortality; Outcomes; Phenotypes; Prognosis; Pulmonary function tests

Indexed keywords

BIOLOGICAL MARKER; NITRIC OXIDE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; ASTHMA; BODY MASS; CANCER RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; EMPHYSEMA; FORCED EXPIRATORY VOLUME; GENETIC ASSOCIATION; HUMAN; INHALATION TEST; INSPIRATORY CAPACITY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; OXYGEN CONSUMPTION; PATIENT ASSESSMENT; PHENOTYPE; PHYSICAL CAPACITY; RISK FACTOR; TOTAL LUNG CAPACITY;

ASTHMA; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG DISEASES, OBSTRUCTIVE; LUNG NEOPLASMS; PHENOTYPE; PULMONARY DIFFUSING CAPACITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RESPIRATORY FUNCTION TESTS; RISK FACTORS;

EID: 84856780025     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.01585     Document Type: Article

References (32)

1. Mason RJ, Broaddus VC, Martin T, King T Jr, Schraufnagel D, Murray JF, Nadel JA. Murray and Nadel's textbook of respiratory medicine, 5th edition. Philadelphia: Saunders/Elsevier; 2010.
2. Han M, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD (clinical commentary). Am J Respir Crit Care Med 2010;182(5):598-604.
3. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348(21):2059-2073.
4. Pelligrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26(5):948-968.
5. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-555.
6. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350(10):1005-1012.
7. Kesten S, Rebuck AS. Is the short-term response to inhaled ßadrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest 1994;105(4):1042-1045.
8. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008;31(4):742-750.
9. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167(3):418-424.
10. Weatherall M, Travers J, Shirtcliffe PM, Marsh SE, Williams MV, Nowitz MR, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009;34(4):812-818.
11. Kuhn TS. The structure of scientific revolutions, 3rd edition. Chicago: University of Chicago; 1996.
12. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159(1):179-187.
13. Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159(4 Pt 1):1267-1271.
14. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Rutten-van Mölken. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis 2010;5:435-444.
15. West WW, Nagai A, Hodgkin JE, Thurlbeck WM. The national institutes of health intermittent positive pressure breathing trial: pathology studies. III. The diagnosis of emphysema. Am Rev Respir Dis 1987;135(1):123-129.
16. Klein JS, Gamsu G, Webb WR, Golden JA, Müller NL. Highresolution CT diagnosis of emphysema in symptomatic patients with normal chest radiographs and isolated low diffusing capacity. Radiology 1992;182(3):817-821.
17. Lee SL, Ra SW, Chae EJ, Seo JB, Lim SY, Kim TH, et al. Validation of the lower limit of normal diffusing capacity for detecting emphysema. Respiration 2011;81(4):287-293.
18. MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26(4):720-735.
19. Owens GR, Rogers RM, Pennock BE, Levin D. The diffusing capacity as a predictor of arterial oxygen desaturation during exercise in patients with chronic obstructive disease. N Engl J Med 1984;310(19):1218-1221.
20. Ries AL, Farrow JT, Clausen JL. Pulmonary function tests cannot predict exercise-induced hypoxemia in chronic obstruction pulmonary disease. Chest 1988;93(3):454-459.
21. Hadeli KO, Siegel EM, Sherrill DL, Beck KC, Enright PL. predictors of oxygen desaturation during submaximal exercise in 8,000 patients. Chest 2001;120(1):88-92.
22. Miller A, Thornton JC, Warshaw R, Anderson H, Teirstein AS, Selikoff IJ. Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history. Am Rev Respir Dis 1983;127(3):270-277.
23. American Thoracic Society. ATS statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med 2002;166(1):111-117. http://thoracic.org/statements/resources/pfet/sixminute.pdf. Accessed October 31, 2011.
24. Salzman SH. The six-minute walk test: clinical and research role, technique, coding, and reimbursement. Chest 2009;135(5):1345-1352.
25. Pichurko B. Exercising your patient: which test(s) and when? Respir Care 2012;57(1):100-110; discussion 110-113.
26. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171(6):591-597.
27. Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, Fishman A, et al; NETT Research Group. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006;173(12):1326-1334.
28. Maldonado F, Bartholmai BJ, Swensen SJ, Midthun DE, Decker PA, Jett JR. Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis. Chest 2010;138(6):1295-1302.
29. Weiss ST. What genes tell us about the pathogenesis of asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181(11):1170-1173.
30. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest 2005;128(4):1989-1994.
31. American Thoracic Society, European Respiratory Society. ATS/ ERS statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168(7):818-900.
32. Jain A, McCarthy, Xu M, Stoller JK. Impact of a clinical decision support system in an electronic health record to enhance detection of alpha-1-antitrypsin deficiency. Chest 2011;140(1):198-204.